Effectiveness of the new generation

transcatheter aortic valve in the real

life studies. Review and meta-analysis by Caretta, Q.
8018
Abstract. – OBJECTIVE: The aim of the me-
ta-analysis was to assess post-procedural out-
come of the new generation of transcatheter 
aortic valve implantation (TAVI) devices, focus-
ing on the transfemoral and balloon-expandable 
SAPIEN 3 (Edwards Lifesciences Inc., Irvine, CA, 
USA), the self-expanding CoreValveTM Evolut se-
ries R and PRO (R/PRO)TM (Medtronic Inc., Min-
neapolis, MN, USA) and ACURATE neo™ tran-
scatheter aortic valve (Symetis SA, a Boston 
Scientific company, Ecublens, Switzerland).
MATERIALS AND METHODS: All observa-
tional studies were retrieved through PubMed 
computerized database from January 2014 un-
til June 30th, 2019. The risk difference (RD) with 
the 95% confidence interval (CI) was used to as-
sess the effectiveness of the intervention un-
der comparison. The primary end point was 30-
day mortality. Safety end points included: (i) 
stroke, (ii) moderate/severe paravalvular leak, 
and (iii) the need for new permanent pacemak-
er implantation.
RESULTS: Meta-analysis demonstrated no 
significant differences as regards to either 30-
day mortality or stroke for all the groups of pros-
theses under comparison. ACURATE neo was 
associated with significantly less new perma-
nent pacemaker implantation compared to SAPI-
EN 3 (RD: -0.06; 95% CI -0.08 to -0.03; p<0.0001; 
I2=0%) or to EVOLUT R/PRO (RD: -0.06; 95% CI 
-0.09 to -0.02; p=0.0009; I2=0%). A significant re-
duction of new permanent pacemaker need was 
observed in the group of patients implanted with 
SAPIEN 3 compared to EVOLUT R/PRO (RD: 
-0.07; 95% CI -0.09 to -0.04; p<0.00001; I2=7%). 
The occurrence of moderate/severe leak was 
significantly increased in the group of patients 
implanted with ACURATE neo vs. SAPIEN 3 (RD: 
0.04; 95% CI 0.02 to 0.05; p<0.00001; I2=0%). 
No significant differences were found between 
ACURATE neo vs. EVOLUT R/PRO (RD: -0.01; 
95% CI -0.04 to 0.02; p=0.69; I2=0%) and between 
SAPIEN 3 vs. EVOLUT R/PRO (RD: -0.01; 95% CI 
-0.04 to 0.01; p=0.28; I2=73%). 
CONCLUSIONS: The results of the meta-anal-
ysis show that: (1) ACURATE neo was associat-
ed with significantly less new permanent pace-
maker implantation than SAPIEN 3 and EVOLUT 
R/PRO; (2) SAPIEN 3 had significantly lower oc-
currence of moderate/severe valvular leak than 
ACURATE neo.
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Introduction
Transcatheter aortic valve implantation (TAVI) 
is recognized as an effective therapy for the treat-
ment of aortic stenosis in high, intermediate, and 
even low-risk operable patients1,2. 
Recent randomized trials of TAVI showed 
that, in patients who were at intermediate or high 
risk for death with surgery, TAVI was either su-
perior or noninferior to standard therapies, in-
cluding SAVR3-14.
As a result of continuous TAVI evolution, sev-
eral new generation transcatheter heart valves 
have been developed incorporating features (i.e., 
lower profile, easier positioning, repositionability, 
and recoverability) addressed to minimize proce-
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dural complications such as paravalvular regur-
gitation, valve malpositioning, vascular compli-
cations, and conduction disorders and to improve 
clinical outcomes15-17.
The aim of the meta-analysis was to compare 
the clinical outcome of the new generation tran-
scatheter aortic valves, focusing on real life stud-
ies, either as a complement to Randomized Con-
trolled Trials (RCTs), and to provide new insight 
on the “effectiveness” of the treatments adminis-
tered in everyday clinical practice in patients with 
severe aortic stenosis, undergoing transfemoral 
TAVI.
Materials and Methods
This review and meta-analysis were performed 
in accordance with the PRISMA (Preferred Re-
porting Items for Systematic Reviews and Me-
ta-Analyses) statement18. 
Study Definition
We searched through PubMed computerized 
database for observational studies (Obs.) per-
forming a direct comparison of almost two of 
the newest heart valves: the balloon-expandable 
SAPIEN 3 (Edwards Lifesciences Inc., Irvine, 
CA, USA), the self-expanding CoreValveTM Evo-
lut series R, and PRO (R/PRO)TM (Medtronic Inc., 
Minneapolis, MN, USA) and ACURATE neo™ 
transcatheter aortic prosthesis (Symetis SA, a 
Boston Scientific company, Ecublens, Switzer-
land) in patients with severe aortic stenosis un-
dergoing transfemoral TAVI. The reference lists 
of the retrieved full-text articles were also exam-
ined to identify potentially relevant studies not 
selected by the electronic search. The search was 
restricted to English-language journals. Studies 
on patients undergoing direct aortic or transapical 
TAVI were excluded. The search was performed 
from January 2014 to June 30th, 2019. Two inves-
tigators independently performed the eligibility 
screening with the aim to include only studies 
that report 30-day mortality and/or at least one of 
the safety endpoints under evaluation. In case of 
disagreement, consensus was obtained after con-
sulting a third reviewer.
Outcomes
The primary end point was 30-day mortality. 
Safety end points included: (i) stroke, (ii) mod-
erate/severe paravalvular leak, and (iii) the need 
for new permanent pacemaker implantation. In-
deed, to avoid risk of bias, due to unobserved or 
inaccurately measured confounders, we included 
in the meta-analysis the data related to the overall 
population of patients from the selected studies.
Statistical Analysis
The meta-analysis was performed using Re-
view Manager (RevMan) [Computer program] 
Version 5.3. (Copenhagen: The Nordic Cochrane 
Centre, The Cochrane Collaboration, 2014) using 
the risk difference (RD) with the 95% Confidence 
Interval (CI), and the absolute risk reductions 
were calculated using the Mantel-Haenszel ran-
dom-effect model to take into account possible 
heterogeneity among studies. We performed the 
analysis using the risk difference instead of the 
relative risk because the differences between the 
absolute risks give a better representation of the 
effectiveness of the interventions under compar-
ison.
We evaluated the effectiveness of the prosthet-
ic implanted valves by comparing the following 
groups of patients: (i) ACURATE neo vs. SAPI-
EN 3, (ii) ACURATE neo vs. EVOLUT R/PRO, 
and (iii) SAPIEN 3 vs. EVOLUT R/PRO. 
A Forest plot was used for a graphical presen-
tation of the results. The selected studies were 
examined to assess the homogeneity/heterogene-
ity of the results by visually inspecting the CIs 
of the risk estimates in the different studies and 
computing the Cochran’s Q test and I2 statistics19. 
A bidirectional α error of < 0.05 was defined as 
statistically significant. 
Results
Of 1,686 studies identified for screening, the 
systematic review selected 15 Obs.20-34 that meet 
the inclusion criteria and were included in the 
meta-analysis (Figure 1). The selected studies 
included 9,100 patients. Specifically, ACURATE 
neo was implanted in 2,294 patients, EVOLUT 
R/PRO in 2,742 patients and SAPIEN 3 in 4,064 
patients (Table I). Six studies compared the ACU-
RATE neo vs. SAPIEN 320-24 and/or EVOLUT R/
PRO21,24,25, and 11 studies SAPIEN 3 vs. EVOLUT 
R/PRO21,24,26-34. Two studies included all the TAVI 
valves under evaluation21-24. The characteristics of 
the selected studies are reported in Table I.
Meta-analysis demonstrated no significant dif-
ferences as regards to either 30-day mortality and 
stroke for all the groups of prostheses under com-
parison. In particular:
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- 30-day mortality was lower, non-signifi-
cantly, in the comparison between SAPIEN 
3 (RD: 0.01; 95% CI -0.01 to 0.02; p=0.31; 
I2=0%) or EVOLUT R/PRO (RD: 0.01; 95% 
CI -0.00 to 0.03; p=0.12; I2=0%) vs. the ACU-
RATE neo (Figure 2). Again, a lower mortal-
ity, not significant, was observed in the com-
parison between SAPIEN 3 vs. EVOLUT R/
PRO (RD -0.00; 95% CI -0.01 to 0.01; p=0.59; 
I2=0%) (Figure 2). 
- the occurrence of stroke was similar in all 
the comparisons (Figure 3). 
Indeed, the need for new permanent pacemak-
er implantation was significantly reduced in the 
patients implanted with ACURATE neo with re-
spect to SAPIEN 3 (RD: -0.06; 95% CI -0.08 to 
-0.03; p<0.0001; I2=0%) and EVOLUT R/PRO 
(RD: -0.06; 95% CI -0.09 to -0.02; p=0.0009; 
I2=0%). A significant lower need for new per-
manent pacemaker was observed also in patients 
implanted with SAPIEN 3 compared to EVO-
LUT R/PRO (RD: -0.07; 95% CI -0.09 to -0.04; 
p<0.00001; I2=7%) (Figure 4). 
On the contrary, the occurrence of moderate/
severe postprocedural leak increased significant-
ly in the comparison between ACURATE neo 
vs. SAPIEN 3 (RD: 0.04; 95% CI 0.02 to 0.05; 
p<0.00001; I2=0%) (Figure 5). While the occur-
rence of postprocedural leak in the comparison 
between ACURATE neo vs. EVOLUT R/PRO 
was similar (RD: -0.01; 95% CI -0.04 to 0.02; 
p=0.69; I2=0%). Also, the comparison between 
SAPIEN 3 vs. EVOLUT R/PRO, did not show 
significant differences, but high heterogeneity 
(I2=73%) values were observed (Figure 5). 
Discussion
The technological progress and the most ac-
curate indications to TAVI have not completely 
solved the post-procedural adverse events, such as 
the need for new permanent pacemaker implanta-
tion35, the periprosthetic leak31,36, and stroke37. New 
generation of TAVI devices have been designed to 
reduce the profile of the delivery catheter, enable 
repositioning and the ability to recover, facilitate 
the technical procedure, and reduce TAVI-related 
complications17. However, Evidence-Based Med-
icine and Clinical Research on their safety and 
Figure 1. Flow-chart of the study selection process.


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































M.C. Acconcia, Q. Caretta, L. Monzo, G. Tanzilli, A. Sili Scavalli, D. Sergi, M. Di Luozzo, et al. 
8022
effectiveness are limited and studies are mainly 
designed to compare the balloon-expandable vs. 
self-expandable valves without making a head-
to-head comparison of the latest generation of 
prostheses26,34. Three trials, the SCOPE I (Clin-
icalTrial.gov Identifier: NCT03011346), SCOPE 
II (ClinicalTrial.gov Identifier: NCT03192813), 
designed to perform an head-to-head comparison 
of the latest valve prostheses (ACURATE neo vs. 
SAPIEN 3 and ACURATE neo vs. EVOLUT R/
PRO, respectively) and the ACURATE IDE (Clin-
icalTrial.gov Identifier: NCT03735667) designed 
to compare the ACURATE neo with Edwards 
SAPIEN 3 and Medtronic CoreValve Evolut R 
or Evolut PRO are still ongoing (see: https://clini-
caltrials.gov). Therefore, due to the lack of RCTs, 
we designed our meta-analysis to evaluate 30-day 
mortality and postprocedural adverse events in 
some new TAVI devices as SAPIEN 3, EVOLUT 
series (R/PRO) and the ACURATE neo from the 
real world observational data. Indeed Obs. can 
provide information on the daily clinical practice 
in the overall population undergoing transfemoral 
TAVI without rigorous exclusion criteria. 
The main finding from our meta-analy-
sis comes from: (i) a significant lower need for 
new pacemaker implantation in the group of pa-
tients implanted with ACURATE neo compared 
to SAPIEN 3 (p<0.0001) and EVOLUT R/PRO 
(p=0.0009) and, (ii) a significant higher postpro-
cedural leak in the group of patients implanted 
with ACURATE neo compared to SAPIEN 3 
(p<0.00001).
SAPIEN 3 and EVOLUT R/PRO heart valves 
did not show differences in the incidence of leak 
after TAVI (Figure 5). However, a higher occur-
Figure 2. Mortality at 30-day. ACURATE neo vs. (i) SAPIEN 3, (ii) EVOLUT R/PRO. SAPIEN 3 vs. EVOLUT R/PRO. 
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rence of new permanent pacemaker implantation 
was observed in the group of patients implanted 
with the EVOLUT R/PRO valve (p<0.00001) 
(Figure 4).
Moreover, we have to emphasize that: (i) we 
included in the meta-analysis all data available 
from Obs., (ii) patient population were homoge-
neous each other, as demonstrated by the I2 statis-
tics equal to 0 in many comparisons (Figure 2-5).
Indeed, despite the risks of bias due to unmea-
sured confounders, Obs. often provide the best 
available evidence of treatment effectiveness38. 
Anglemyer et al39, analyzing the impact of the 
study design, Obs. vs. RCTs, on the estimate of 
the measure of effect, found that there was in-
creasing evidence that in most cases RCTs and 
non-randomized studies yielded similar findings, 
when the studies had homogeneous data. 
Furthermore, we can witness the evolution of 
clinical research every day. Thus, it can be ob-
served that the acceptance of observational data 
occurs more and more frequently, both through 
the use of the registry and through the implemen-
tation of capillary networks that record the daily 
clinical practice40.
In conclusion our findings, showing adverse 
outcomes related to the need for new permanent 
pacemaker implantation and the occurrence of 
postprocedural moderate/severe aortic insuffi-
ciency, could be related to the structural diversity 
of valve prostheses. However, the issue seems to 
remain unresolved and warrants further investi-
gations. 
Our meta-analysis, based on data from Obs., 
could overestimate the treatments effect due to 
the lack of randomization41,42. RCTs on efficacy of 
the new generation of TAVI devices, considered 
a key tool for comparative effectiveness research, 
are still recruiting. Their findings may help pro-
vide answers to the limitations of Obs.
Figure 3. Incidence of stroke.
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Figure 4. The need for new permanent pacemaker implantation. 
Figure 5. Incidence of moderate/severe paravalvular leak. 
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Conclusions
The meta-analysis shows that: (i) ACURATE 
neo required significant less new permanent post-
procedural pacemaker implantation than SAPIEN 
3 and EVOLUT R/PRO, (ii) SAPIEN 3 had signif-
icant lower occurrence of moderate/severe valvu-
lar leak than ACURATE neo.
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